Community Events

8 Mar 2024
HHP I&E Workshop
Evaluating Science through the Lens of Commercialisation

Evaluating Science through the Lens of Commercialization

From left to right: Mr Seck Yee Kwang, Mr Lim Jui, and distinguished panellists Dr Nikhil Mutyal, Mr Navjeewan Khosla and Ms Miemie Strydom.

BMSIPO and SGInnovate came together to organise a panel on how pharmaceutical multinational corporations (MNCs) and investors evaluate innovative scientific projects from a commercialisation perspective.

Over 80 attendees from local biomedtechs, pharma companies, venture capitalists (VCs) and academics gathered to gain insights from the panel, which included Dr Nikhil Mutyal, Executive Director of Business Development and Licensing at MSD, Navjeewan Khosla, Partner at Novo Holdings Equity Asia, as well as Miemie Strydom, Director New Business Development at Johnson & Johnson Innovative Medicine, Asia Pacific.

The focus of the night’s conversation was on how big pharma approaches external innovation partnerships, namely with biomedtech start-ups. “There’s a reason why we’ve outsourced innovation. Biotech startups and universities are better equipped to drive discoveries, and that’s a model that will continue to exist,” emphasised Miemie Strydom.

In a conversation moderated by Lim Jui, CEO of SG Innovate, the panelists delved into how big pharma decides whom to invest in, partner with, or collaborate with, and these methodologies are integrated to create their 'wish-list.' A key takeaway was the importance of a robust pitch deck that captures the vision of how the technology will be commercialised and delivered to patients. Beyond the open discussion and opportunities to pose questions to relevant stakeholders in pharma and investors, participants found the event to be a fruitful networking session.

Community Events

A*STAR celebrates International Women's Day